Myriad Genetics Misses Q2 Revenue by $15.3M, Slashes Guidance, and Suspends EBITDA Outlook
MYGN is trading near its 52-week low of $3.53 (8.7% above the low).
Summary
Myriad Genetics missed Q2 revenue estimates by $15.3M, cut full-year revenue guidance, and suspended its EBITDA outlook amid declining test reimbursement and Prenatal Health volumes.
Key Events · Earnings and Guidance · MYGN
-
Q2 Revenue Miss and Decline
Revenue of $190.7M fell 11% YoY and missed consensus by $15.3M, driven by a 9% drop in average revenue per test and an $11M reduction from prior-period collection estimate changes.
-
Full-Year Guidance Cut
2026 revenue guidance was revised down to $770–$790M from a prior implied ~$800M+, and adjusted EBITDA guidance was suspended entirely, reflecting lower Prenatal Health volumes and conservative reimbursement assumptions.
-
Cash Burn and Liquidity
Cash and equivalents dropped to $115.2M from $149.6M at year-end 2025, with adjusted free cash outflow of $10.9M in Q2 and $30.8M in the first half of 2026.
-
Strategic Efficiency Initiative
Management launched 'Ascend,' an efficiency and scalability program supported by a leading professional services firm, alongside a rigorous product portfolio evaluation to optimize capital allocation.
Analysis · MYGN · Life Sciences
A sharp 11% year-over-year revenue decline to $190.7 million missed consensus by $15.3 million, driven by a 9% drop in average revenue per test—including an $11 million hit from prior-period collection estimate changes—and a 9% volume decline in Prenatal Health. The GAAP net loss widened to $43.2 million, while cash reserves fell to $115.2 million from $149.6 million at year-end. Management slashed full-year revenue guidance to $770–$790 million and suspended adjusted EBITDA guidance entirely, signaling deep uncertainty about near-term profitability. An 'Ascend' efficiency program with outside consultants is now underway, but the combination of top-line weakness, reimbursement pressure, and suspended profit guidance raises serious questions about the pace of any turnaround.
How filings like this one have moved
In the 30 days to Sep 16, 2026, 35.8% of the 1190 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.45%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MYGN was trading at $3.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $507.2M. The 52-week trading range was $3.53 to $8.59. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.